1MUV2 (1MUV2) Fair Value & Analysis
Financial Services · IT · Market cap €63.7B
Fair value as of: Jul 3, 2026
From 18 valuation models · updated today
Share price +13.5% over the past month.
Price vs Fair Value (12 months)
12‑month range €440.96 – €583.49 · fair‑value band €502.02 – €836.69 · the €500.40 price screens below the €669.36 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
1MUV2 (1MUV2) currently trades at €500.40, while our model-based Fair Value estimate is €669.36 — implying the stock looks roughly 33.8% undervalued today. We read business quality at 57/100 (solid quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, 1MUV2 generated revenue of €61.4B at a net margin of 11.0%. Revenue declined 6.0% year over year. It earns a return on equity of 19.9%. Net debt stands at €1.9B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München engages in the insurance and reinsurance businesses worldwide. The company operates through six segments: Life and Health Reinsurance, Property-Casualty Reinsurance, Global Specialty Insurance, ERGO Life and Health Germany, ERGO Property-Casualty Germany, and ERGO International. The company offers life and health reinsurance solutions, such as digital underwriting and advanced analytics solutions, health insurance management system, financial market risks, financing, portfolio risk management, digitalized investment-linked solution, data analytics, underwriting and claims, medical research, capital management, and health market, as well as MIRA digital suite that includes MIRA PoS, MIRApply insured and physician, claims risk assessment, and CLARA plus. It also provides property and casualty reinsurance solutions, including agricultural reinsurance; business advisory, personal lines, portfolio management, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
1MUV2 reported revenue of €62.3B in FY2025 versus €64.5B in FY2021, a compound −0.8%/yr. Reported net income was €6.1B in FY2025, compounding +20.2%/yr from FY2021.
Is 1MUV2 fairly valued? → Check now
Recent news
- Lard Friese, CEO of Aegon, becomes Chair of the Geneva Association
- Should Value Investors Buy Mnchener RckversicherungsGesellschaft (MURGY) Stock?
- Universal's Insurance Subsidiaries Complete 2026-2027 Reinsurance Program
- Why The Story Around Munich Re (XTRA:MUV2) Is Shifting After New Analyst Target Cuts
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Insurance - Reinsurance stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| MURGF MURGF | $536.50 | $545.86 | +2% |
| MURGY MURGY | $10.89 | $10.44 | -4% |
| MUV2 MUV2 | €452.30 | €848.03 | +87% |
| Swiss Re AG SSREY | $38.99 | $52.50 | +35% |
| Hannover Rück SE HVRRF | $275.00 | $550.00 | +100% |
| Everest Group E1VE34 | R$440.32 | R$201.03 | -54% |
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is 1MUV2 (1MUV2) undervalued?
What is the fair value of 1MUV2?
What is the quality score of 1MUV2?
What is the revenue of 1MUV2 (1MUV2)?
What is the net profit margin of 1MUV2?
Does 1MUV2 pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.